Profile data is unavailable for this security.
About the company
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
- Revenue in USD (TTM)837.32m
- Net income in USD-2.11bn
- Incorporated2018
- Employees2.84k
- LocationTilray Brands Inc265 Talbot Street WestLEAMINGTON N8H 5L4CanadaCAN
- Phone+1 (519) 322-8800
- Fax+1 (416) 934-2141
- Websitehttps://www.tilray.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elite Pharmaceuticals Inc | 122.89m | 13.92m | 484.60m | 68.00 | 36.97 | 7.86 | 31.15 | 3.94 | 0.0122 | 0.0122 | 0.1131 | 0.0574 | 1.20 | 3.60 | 3.94 | 1,807,255.00 | 13.55 | 13.18 | 15.31 | 16.01 | 52.66 | 47.19 | 11.33 | 13.97 | 6.34 | 2.37 | 0.0681 | 0.00 | 48.42 | 36.10 | -121.46 | -- | 135.38 | -- |
| Emergent Biosolutions Inc | 788.90m | 75.90m | 579.30m | 900.00 | 8.52 | 0.9979 | 3.33 | 0.7343 | 1.29 | 1.29 | 14.20 | 11.05 | 0.5369 | 1.06 | 5.83 | 876,555.60 | 5.17 | -5.03 | 5.90 | -6.47 | 54.58 | 49.01 | 9.62 | -9.76 | 3.15 | 1.85 | 0.5324 | -- | -0.5432 | -1.15 | 74.94 | -- | -25.06 | -- |
| CorMedix Inc | 214.30m | 162.50m | 597.22m | 64.00 | 3.69 | 1.59 | 3.58 | 2.79 | 2.05 | 2.05 | 2.97 | 4.78 | 0.5174 | 0.8901 | 2.44 | 3,348,495.00 | 39.23 | -42.85 | 48.05 | -49.82 | 92.61 | 91.93 | 75.83 | -327.99 | 1.73 | -- | 0.2802 | -- | -- | 173.65 | 61.31 | -- | 25.91 | -- |
| Rigel Pharmaceuticals Inc | 282.08m | 113.30m | 624.59m | 162.00 | 5.58 | 5.31 | 5.40 | 2.21 | 6.17 | 6.17 | 15.36 | 6.48 | 1.48 | 2.15 | 7.37 | 1,741,210.00 | 59.33 | -16.62 | 97.15 | -28.36 | 93.10 | 95.63 | 40.17 | -16.88 | 2.14 | 25.77 | 0.3368 | -- | 53.38 | 24.77 | 169.69 | -- | -22.92 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| ASP Isotopes Inc | 8.38m | -105.56m | 716.88m | 136.00 | -- | 7.22 | -- | 85.51 | -1.43 | -1.43 | 0.1124 | 0.7932 | 0.0541 | 8.86 | 0.884 | 61,642.43 | -68.21 | -- | -85.13 | -- | 23.00 | -- | -1,261.23 | -- | 6.10 | -0.6787 | 0.5382 | -- | 857.03 | -- | -115.60 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 338.99m | 28.55m | 787.36m | 253.00 | 34.47 | -- | 25.85 | 2.32 | 0.1404 | 0.1404 | 2.00 | -1.62 | 0.863 | -- | 3.45 | 1,339,870.00 | 7.27 | -6.08 | 11.57 | -7.13 | -- | -- | 8.42 | -11.01 | -- | 4.73 | 1.82 | -- | -20.63 | -3.89 | 100.09 | -56.87 | -54.38 | -- |
| Esperion Therapeutics Inc | 303.80m | -105.83m | 793.69m | 304.00 | -- | -- | -- | 2.61 | -0.5358 | -0.5358 | 1.54 | -2.20 | 0.896 | 1.35 | 3.25 | 999,348.70 | -31.21 | -61.82 | -138.14 | -101.31 | 58.20 | 81.27 | -34.84 | -109.30 | 0.7017 | -0.3928 | 4.08 | -- | 185.66 | 17.50 | 75.27 | -- | -19.76 | -- |
| Pacira Biosciences Inc | 716.79m | 21.44m | 865.98m | 790.00 | 45.18 | 1.24 | 7.70 | 1.21 | 0.4664 | 0.4664 | 15.70 | 16.93 | 0.5085 | 1.11 | 6.64 | 907,330.40 | 1.52 | 1.87 | 1.78 | 2.22 | 79.17 | 73.06 | 2.99 | 4.84 | 3.78 | -- | 0.3413 | 0.00 | 3.85 | 10.73 | -337.30 | -- | 0.9219 | -- |
| Tilray Brands Inc | 837.32m | -2.11bn | 897.10m | 2.84k | -- | 0.5679 | -- | 1.07 | -22.10 | -22.10 | 8.27 | 13.56 | 0.2662 | 2.19 | 7.55 | 294,624.60 | -66.88 | -- | -72.47 | -- | 28.02 | -- | -251.21 | -- | 1.72 | -2.41 | 0.1605 | -- | 4.10 | -- | -792.62 | -- | -- | -- |
| Theravance Biopharma Inc | 80.33m | 29.34m | 988.11m | 97.00 | 34.66 | 4.25 | 31.88 | 12.30 | 0.5626 | 0.5626 | 1.59 | 4.59 | 0.2082 | -- | 4.58 | 828,113.40 | 7.61 | -34.51 | 8.26 | -40.08 | -- | -- | 36.53 | -254.51 | -- | -- | 0.1216 | -- | 12.12 | -2.59 | -2.22 | -- | -36.34 | -- |
| Phathom Pharmaceuticals Inc | 147.19m | -274.55m | 995.79m | 427.00 | -- | -- | -- | 6.77 | -3.81 | -3.81 | 2.04 | -5.95 | 0.4693 | 5.58 | 3.83 | 344,707.30 | -87.53 | -72.89 | -117.10 | -84.11 | 87.25 | -- | -186.53 | -1,799.61 | 2.19 | -3.35 | 3.68 | -- | 8,001.47 | -- | -65.84 | -- | 0.4505 | -- |
| Xeris Biopharma Holdings Inc | 266.14m | -15.64m | 1.15bn | 394.00 | -- | -- | -- | 4.34 | -0.1033 | -0.1033 | 1.67 | -0.0052 | 0.77 | 0.7301 | 5.61 | 675,474.60 | -4.52 | -31.61 | -6.46 | -42.28 | 84.56 | 79.76 | -5.88 | -77.77 | 1.35 | 0.3853 | 1.00 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
| EyePoint Inc | 42.34m | -205.75m | 1.16bn | 165.00 | -- | 4.89 | -- | 27.51 | -2.99 | -2.99 | 0.617 | 2.88 | 0.1532 | 1.02 | 59.51 | 256,606.10 | -74.47 | -35.88 | -86.87 | -42.05 | 94.08 | 84.82 | -485.95 | -201.78 | 7.11 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| Day One Biopharmaceuticals Inc | 133.67m | -151.76m | 1.20bn | 184.00 | -- | 2.67 | -- | 9.00 | -1.48 | -1.48 | 1.30 | 4.39 | 0.2399 | 2.88 | 10.53 | 738,519.30 | -27.23 | -39.78 | -29.80 | -43.02 | 89.44 | -- | -113.53 | -414.14 | 8.55 | -- | 0.00 | -- | -- | -- | 49.45 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Tilray Brands Inc's reporting currency: US Dollar USD
6.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tidal Investments LLCas of 30 Sep 2025 | 2.61m | 2.25% |
| HRT Financial LPas of 30 Sep 2025 | 1.48m | 1.28% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 974.76k | 0.84% |
| UBS Securities LLCas of 31 Dec 2025 | 691.00k | 0.60% |
| Millennium Management LLCas of 30 Sep 2025 | 494.23k | 0.43% |
| Jane Street Capital LLCas of 30 Sep 2025 | 441.35k | 0.38% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Sep 2025 | 368.00k | 0.32% |
| Global X Investments Canada, Inc.as of 31 Dec 2025 | 340.69k | 0.29% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 339.85k | 0.29% |
| Global X Management Co. LLCas of 30 Sep 2025 | 336.00k | 0.29% |
More ▼
Data from 30 Sep 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
